Conduit Pharmaceuticals (CDT) announces that its board of directors has approved a 1-for-15 reverse stock split of the Company’s common stock. The Company’s stockholders approved the reverse stock split proposal at the Company’s Special Meeting of Stockholders held on May 5, 2025. They granted the board of directors the authority to determine the exact split ratio and when to proceed with the reverse stock split.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals receives patent approval for AZD1656
- Conduit Pharmaceuticals files composition of matter patent for AZD5904
- Conduit Pharmaceuticals Approves Reverse Stock Split Amendments
- Conduit Pharmaceuticals files to sell 2.2M shares of common stock for holders
- Conduit Pharmaceuticals announces Regan appointed as CEO